ViaNautis Bio
PrivateLast Round
Series A
Nov 13, 2023
Total Funding Raised
$27.89M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ViaNautis Bio operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Series A round in November 2023.
ViaNautis Bio is a biotechnology company developing a nanomedicine platform to deliver genetic therapies across biological barriers for diseases such as cystic fibrosis and central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ViaNautis Bio Comparables
Compare ViaNautis Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genedit | 88% | |
| Nanite, Inc. | 84% | |
| Deliver Biosciences | 80% |
For institutional investors. Book with your work email.
ViaNautis Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 13, 2023 | ||||
| Seed | Mar 29, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ViaNautis Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCB Ventures | Series A |
| BGF | Series A |
| Origin Capital | Series A, Seed |
| o2h ventures | Series A, Seed |
| 4BIO Capital | Series A |
| Meltwind Advisory | Series A, Seed |
| Cystic Fibrosis Foundation | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 181% MoM, reaching 1.6K.
- Mar 13, 2025
Grew 18% QoQ, from 38 to 45 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 9, 2026
ViaNautis Bio Ltd. is developing polyNaut, a delivery platform for nanobody-guided delivery of DNA and mRNA to specific cells and tissues, including regenerative genetic payloads at or around lesion sites, in United Kingdom as of Sep 9th '26.
For institutional investors. Book with your work email.
ViaNautis Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ViaNautis Bio's valuation, stock price, and market status.
Is ViaNautis Bio a public or private company?
ViaNautis Bio is a private company.
What is the current stock price of ViaNautis Bio?
ViaNautis Bio is a private company, so its shares have no public market price. Caplight tracks ViaNautis Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ViaNautis Bio worth (valuation)?
Valuation information for ViaNautis Bio is not publicly available.
Can I buy ViaNautis Bio stock?
ViaNautis Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ViaNautis Bio's last funding round?
ViaNautis Bio's most recent funding round was Series A on November 13, 2023.
Who are the main investors in ViaNautis Bio?
Key investors in ViaNautis Bio include UCB Ventures, BGF, Origin Capital, 4BIO Capital, Meltwind Advisory.
Will ViaNautis Bio IPO soon?
No public IPO plans have been announced for ViaNautis Bio.
How can I track ViaNautis Bio secondary market activity?
Caplight tracks bids, offers, and trades in ViaNautis Bio's shares on secondary markets.